Cargando…

Long-term Combination Therapy With α-Blockers and 5α-Reductase Inhibitors in Benign Prostatic Hyperplasia: Patient Adherence and Causes of Withdrawal From Medication

PURPOSE: To investigate long-term therapeutic effects and patient adherence to a combination therapy of a 5α-reductase inhibitor and an α-blocker and to identify causes of withdrawal from medication in patients with clinical benign prostatic hyperplasia (BPH). METHODS: BPH patients with lower urinar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ong, Hueih Ling, Liao, Chun-Hou, Kuo, Hann-Chorng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Continence Society 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209571/ https://www.ncbi.nlm.nih.gov/pubmed/28043104 http://dx.doi.org/10.5213/inj.1632526.263

Ejemplares similares

Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia
por: Zhang, Jiandong, et al.
Publicado: (2023)

α-Blocker Monotherapy and α-Blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years' Long-Term Results
por: Shin, Teak Jun, et al.
Publicado: (2012)

Effect of Shifting from Combination Therapy to Monotherapy of α-Blockers or 5α-Reductase Inhibitors on Prostate Volume and Symptoms in Patients with Benign Prostatic Hyperplasia
por: Kim, Hyoung Woo, et al.
Publicado: (2011)

Current consensus and controversy on the treatment of male lower urinary tract symptoms/benign prostatic hyperplasia
por: Liao, Chun-Hou, et al.
Publicado: (2017)

5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer
por: Robinson, David, et al.
Publicado: (2015)

α1-Blockers and 5α-Reductase Inhibitors Are the Most Recommended Drugs in Treating Benign Prostatic Hyperplasia: An Evidence-Based Evaluation of Clinical Practice Guidelines
por: Xu, Xiao-Feng, et al.
Publicado: (2020)

Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination
por: Shum, Cheuk Fan, et al.
Publicado: (2017)

Treating overactive bladder symptoms after transurethral prostatic surgery for benign prostatic hyperplasia – Which medication to choose?
por: Lee, Cheng-Ling, et al.
Publicado: (2023)

Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation?
por: Chiang, Bing-Juin, et al.
Publicado: (2019)

Ramelteon combined with an α(1)-blocker decreases nocturia in men with benign prostatic hyperplasia
por: Kawahara, Takashi, et al.
Publicado: (2013)

Current consensus and controversy on the diagnosis of male lower urinary tract symptoms/benign prostatic hyperplasia
por: Lee, Cheng-Ling, et al.
Publicado: (2017)

Transurethral Incision of the Bladder Neck with or without Additional Procedure Resumes Spontaneous Voiding in Female Voiding Dysfunction—A Long-Term Retrospective Follow-Up
por: Ong, Hueih-Ling, et al.
Publicado: (2023)

A Dual 5α-Reductase Inhibitor Dutasteride Caused Reductions in Vascular Density and Area in Benign Prostatic Hyperplasia
por: Zaitsu, Masayoshi, et al.
Publicado: (2013)

The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
por: Kim, Eric H., et al.
Publicado: (2018)

Precision medicine in the diagnosis and treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia
por: Chen, Jing-Liang, et al.
Publicado: (2019)

Personalized therapeutics of α(1)-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
por: Zhu, Ling-ling, et al.
Publicado: (2015)

Effect of 5α-reductase inhibitors on the efficiency of thulium:yttrium-aluminium-garnet (RevoLix®) vaporesection for treating benign prostatic hyperplasia
por: Chung, Jae Seung, et al.
Publicado: (2020)

Cinnamomi Cortex (Cinnamomum verum) Suppresses Testosterone-induced Benign Prostatic Hyperplasia by Regulating 5α-reductase
por: Choi, Hyun-Myung, et al.
Publicado: (2016)

Pao Pereira Extract Attenuates Testosterone-Induced Benign Prostatic Hyperplasia in Rats by inhibiting 5α-Reductase
por: Liu, Jiakuan, et al.
Publicado: (2019)

Increased Serum C-Reactive Protein Level Is Associated with Increased Storage Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia
por: Hung, Shun-Fa, et al.
Publicado: (2014)

5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data
por: Del Giudice, Francesco, et al.
Publicado: (2023)

Therapeutic efficacy of mirabegron 25 mg monotherapy in patients with nocturia-predominant hypersensitive bladder
por: Lee, Cheng-Ling, et al.
Publicado: (2019)

Seasonal Changes in Lower Urinary Tract Symptoms in Japanese Men With Benign Prostatic Hyperplasia Treated With α(1)-Blockers
por: Kobayashi, Minoru, et al.
Publicado: (2017)

Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia
por: Cho, Kang Jun, et al.
Publicado: (2011)

Clinical Effects of Discontinuing 5-Alpha Reductase Inhibitor in Patients With Benign Prostatic Hyperplasia
por: Kim, Won, et al.
Publicado: (2014)

A meta-analysis of the vascular-related safety profile and efficacy of α-adrenergic blockers for symptoms related to benign prostatic hyperplasia
por: Nickel, J C, et al.
Publicado: (2008)

Impact of preoperative 5α-reductase inhibitors on perioperative blood loss in patients with benign prostatic hyperplasia: a meta-analysis of randomized controlled trials
por: Zhu, Yi-Ping, et al.
Publicado: (2015)

Combined effect of polymorphisms in type III 5-α reductase and androgen receptor gene with the risk of benign prostatic hyperplasia in Korea
por: Lee, Chung Lyul, et al.
Publicado: (2016)

Corni Fructus attenuates testosterone-induced benign prostatic hyperplasia by suppressing 5α-reductase and androgen receptor expression in rats
por: Hwangbo, Hyun, et al.
Publicado: (2018)

Upregulation of mir-1199-5p is associated with reduced type 2 5-α reductase expression in benign prostatic hyperplasia
por: Liu, Zhanliang, et al.
Publicado: (2022)

Pathophysiology of benign prostate enlargement and lower urinary tract symptoms: Current concepts
por: Lee, Cheng-Ling, et al.
Publicado: (2017)

Chrysophanic acid reduces testosterone-induced benign prostatic hyperplasia in rats by suppressing 5α-reductase and extracellular signal-regulated kinase
por: Youn, Dong-Hyun, et al.
Publicado: (2016)

Trapa bispinosa Roxb. Pericarp Extract Exerts 5α-Reductase Inhibitory Activity in Castrated Benign Prostatic Hyperplasia Model Mice
por: Fujita, Takashi, et al.
Publicado: (2023)

Predictive Factors for a Satisfactory Treatment Outcome with Intravesical Botulinum Toxin A Injection in Patients with Interstitial Cystitis/Bladder Pain Syndrome
por: Wang, Hsiu-Jen, et al.
Publicado: (2019)

Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia
por: Hagberg, Katrina Wilcox, et al.
Publicado: (2017)

Prospective Factor Analysis of Alpha Blocker Monotherapy Failure in Benign Prostatic Hyperplasia
por: Hong, Kyoung Pyo, et al.
Publicado: (2010)

Cynanchum wilfordii Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Regulating 5α-Reductase and Androgen Receptor Activities in a Rat Model
por: Lee, Gyuok, et al.
Publicado: (2017)

Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
por: Kim, Jae Heon, et al.
Publicado: (2018)

Effect of α-receptor blockers on lower urinary tract symptoms, sexual function and quality of life in young and middle-aged men with benign prostatic hyperplasia
por: Wang, Tongqing, et al.
Publicado: (2017)

Mixture of Corni Fructus and Schisandrae Fructus improves testosterone-induced benign prostatic hyperplasia through regulating 5α-reductase 2 and androgen receptor
por: Hwangbo, Hyun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3ihp05l313kr1q51icdkv28fl3